JERUSALEM, Feb. 25, 2020 /PRNewswire/ -- Intec
Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today
announces that Company management will participate at the following
upcoming investment conferences in March.
Cowen 40th Annual Health Care
Conference
Date: March 2-5, 2020
Company Presentation: Wednesday, March 4, 2020 at 11:20 am (Eastern time)
Location: Boston Marriott Copley Place, Boston, MA
Presenter: Jeffrey A. Meckler,
Vice Chairman and Chief Executive Officer of Intec Pharma
Format: Corporate presentation and One-on-One Investor Meetings
32nd Annual ROTH
Conference
Date: March
15-18, 2020
Company Presentation: Tuesday, March 17, 2020 at
3:30 pm (Pacific
time)
Location: The Ritz Carlton Laguna
Nigel, Dana Point, CA
Presenter: Jeffrey A. Meckler, Vice
Chairman and Chief Executive Officer of Intec Pharma
Format: Panel Discussion and One-on-One Investor Meetings
Oppenheimer's 30th Annual Healthcare
Conference
Date: March 17-18, 2020
Company Presentation: Wednesday, March 18, 2020 at
10:20 am (Eastern time)
Location: Intercontinental Barclay Hotel, New York City, NY
Presenter: Jeffrey A. Meckler,
Vice Chairman and Chief Executive Officer of Intec Pharma
Format: Corporate presentation and One-on-One Investor Meetings
Mr. Meckler's presentations will be webcast live and will be
accessible through the Events section of Intec
Pharma's website at www.intecpharma.com, where they will
also be archived for a period of time.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is in late-stage development for the treatment of
Parkinson's disease symptoms in advanced Parkinson's disease
patients, and AP-cannabinoids, an Accordion Pill to deliver either
or both of the primary cannabinoids contained in Cannabis sativa,
cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain
indications. In addition, the Company has a research collaboration
with Merck & Co.
For more information, visit www.intecpharma.com. Intec
Pharma routinely posts information that may be important to
investors in the Investor Relations section of its
website.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward looking statements about our
expectations, beliefs and intentions. Forward-looking statements
can be identified by the use of forward-looking words such as
"believe", "expect", "intend", "plan", "may", "should", "could",
"might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and we undertake no duty to update or revise any
such statements, whether as a result of new information, future
events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to, the following: our limited operating
history and history of operating losses, our ability to continue as
a going concern, our ability to obtain additional financing, our
ability to successfully operate our business or execute our
business plan, the timing and cost of our clinical trials, the
completion and receiving favorable results in our clinical trials,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to protect and maintain our
intellectual property and licensing arrangements, our ability to
develop, manufacture and commercialize our product candidates, the
risk of product liability claims, the availability of
reimbursement, and the influence of extensive and costly government
regulation. More detailed information about the risks and
uncertainties affecting us is contained under the heading "Risk
Factors" included in our most recent Annual Report on Form 10-K
filed with the SEC on February 27, 2019, and in
other filings that we have made and may make with
the Securities and Exchange Commission in the future.
Intec Pharma Investor Contact:
Will
O'Connor
Stern IR
+1 212-362-1200
will@sternir.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-to-participate-at-three-investment-conferences-in-march-301010738.html
SOURCE Intec Pharma Ltd.